Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474297 | 1.00 | EPHX2 (0.48) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL21863862 | 0.90 | EPHX2 (0.41) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL20616396 | 0.90 | EPHX2 (0.41) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL20616140 | 0.90 | EPHX2 (0.41) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL21222266 | 0.86 | EPHX2 (0.43) | EPHX2FFAR4GRIN1GRIN2B | |
| SCHEMBL20064207 | 0.86 | EPHX2 (0.43) | EPHX2FFAR4GRIN1GRIN2B | |
| SCHEMBL2471998 | 0.84 | EPHX2 (0.56) | EPHX2DGAT1SOAT1 | |
| SCHEMBL2471996 | 0.84 | EPHX2 (0.56) | EPHX2DGAT1SOAT1 | |
| SCHEMBL2477545 | 0.80 | EPHX2 (0.47) | EPHX2ACACBFFAR4DGAT1GRIN1 | |
| SCHEMBL2477548 | 0.80 | EPHX2 (0.47) | EPHX2ACACBFFAR4DGAT1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370441-B1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2370441-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | EPHX2 3294/4885ACACB 3632/4885FFAR4 1747/4885 |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | EPHX2 3294/4885ACACB 3632/4885FFAR4 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.